Peregrine Pharmaceuticals's ( PPHM ) share price has entered into oversold territory with an RSI value of 23.3. The Zacks Consensus Estimate on Peregrine Pharmaceuticals's earnings for the full year period has loss of 0.01 cents over the past two months to $-0.24 per share. Currently, Peregrine Pharmaceuticals is a Zacks #2 Rank ("Buy"), suggesting that now might be a good time to get in on ( PPHM ) after its recent drop.
PEREGRINE PHARM (PPHM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Peregrine Pharmaceuticals is now in Oversold Terri
Post# of 97801
![Avatar](/images/ProfileImages/984076804_464_129571309_0017.gif)
Peregrine Pharmaceuticals is now in Oversold Territory - Tale of the Tape
Read more: http://www.nasdaq.com/article/peregrine-pharm...z2mPw2rn1z
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
![937206596_images.jpg](https://investorshangout.com/images/MYImages/937206596_images.jpg)